Which mechanism of action is unique to ezetimibe among the commonly used lipid-lowering agents?

Explanation

## Ezetimibe: Unique Mechanism of Action **Key Point:** Ezetimibe is the only widely used lipid-lowering agent that selectively inhibits cholesterol absorption at the intestinal brush border by blocking the NPC1L1 transporter. ### Mechanism of Action Details **Ezetimibe's Unique Target:** - Blocks **Niemann-Pick C1-like 1 (NPC1L1) protein** located on the apical membrane of intestinal enterocytes - Prevents entry of dietary and biliary cholesterol into enterocytes - Reduces intestinal cholesterol absorption by ~50% - Does NOT affect hepatic cholesterol synthesis ### Comparison with Other Lipid-Lowering Agents | Agent Class | Mechanism | Site of Action | |-------------|-----------|----------------| | **Ezetimibe** | **NPC1L1 inhibition** | **Intestinal brush border (UNIQUE)** | | Statins | HMG-CoA reductase inhibition | Hepatic mitochondria | | Fibrates | PPAR-α activation | Hepatic & adipose tissue | | PCSK9 inhibitors | LDL receptor upregulation | Hepatic surface | | Bempedoic acid | AMPK activation, XO inhibition | Hepatic | **High-Yield:** Ezetimibe is the **only intestinal cholesterol absorption inhibitor** in routine clinical use. It works synergistically with statins because it targets a different pathway — statins reduce synthesis, ezetimibe reduces absorption. **Clinical Pearl:** Ezetimibe monotherapy reduces LDL-C by ~18–20%, but when combined with a statin, the additional LDL-C reduction is ~15–20% (additive effect). This combination is particularly useful in statin-intolerant patients or those requiring aggressive LDL-C lowering. **Mnemonic:** **"EZETIMIBE = Enterocyte Cholesterol Transport Inhibitor"** — remember it works at the intestinal level, not the liver.